10h
Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch
CEO Michael Morrissey described 2025 as a “transformational year” with “strong growth across all components of our business,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results